20 biggest launches of 2012 were led by Kalydeco and Xtandi

04/10/2013 | Genetic Engineering & Biotechnology News

Vertex Pharmaceuticals' Kalydeco, or ivacaftor, topped Genetic Engineering & Biotechnology News' list of best-selling drugs that were approved and commercialized last year based on 2012 sales figures. Kalydeco generated sales of $171.6 million. Medivation and Astellas Pharma's Xtandi, or enzalutamide, came in second with $71.5 million, followed by Pfizer's Inlyta, or axitinib, with $70.1 million. Rounding out the top five were Onyx Pharmaceuticals' Kyprolis, or carfilzomib, and Roche Holding's Perjeta, or pertuzumab. The list includes the dates of approval in the U.S. and/or Europe.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA